Dr. Dongbo Xu is a research associate currently in the Department of Urology at Roswell Park Comprehensive Cancer Center. He has five working experiences in urothelial carcinoma like cancer treatment, animal models, genetically engineered mouse models, DNA repair, patient organoid, etc.
Dongbo received his Ph.D. degree in Biochemistry and Molecular Biology in 2016 from Wuhan University, China, and started his first postdoctoral position in Harbor Branch Oceanographic Institute, Florida, US. During previous Ph.D. and postdoc experience, Dongbo's research is mainly focused on discovering potential bioactive natural products and their biosynthesis from marine microorganisms. He gains the skills of the whole natural product discovery process from strain isolation to compound NMR analysis, gene manipulation, genome bioinformatics analysis, bioactivity screening, etc. He identified some bioactive compounds with novel structures and potential for preclinical study.
As a drug researcher with a background in lead compound discovery and pharmacodynamics evaluation, he developed his research interest in cancer treatment, which is more translational to develop one potential drug. Since 2018, he has started urothelial carcinoma-related research at Roswell Park Comprehensive Cancer Center. He has expertise in generating genetically engineered mouse models and animal cancer models including tumor xenograft and bladder orthotopic or intravesical models. He is also focused on the research about DNA damage response and NER repair, 3D Patient-derived Organoid and murine organoid, and chemo-drug and immunotherapy treatment.
